A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer | MicrobiomeTrials
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2025-10-07Est. Completion: 2028-08-31
Enrollment target: 285 participants
Locations
Clearview Cancer Institute - Huntsville, Huntsville, Alabama, United States
University of Arizona Cancer Center, Tucson, Arizona, United States
City of Hope, Duarte, California, United States
City of Hope - Orange County Lennar Foundation Cancer Center, Irvine, California, United States
UC San Diego Moores Cancer Center, La Jolla, California, United States
University of California San Diego Medical Center, San Diego, California, United States
UCSF Helen Diller Family CCC, San Francisco, California, United States
University of Colorado Cancer Center, Aurora, Colorado, United States
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
City of Hope® Cancer Center Chicago, Zion, Illinois, United States
Barbara Ann Karmanos Cancer Institute, Detroit, Maine, United States
Maryland Oncology Hematology - Annapolis, Annapolis, Maryland, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Other microbiome trials you might be interested in
Recurrent Breast CarcinomaStage III Breast Cancer AJCC v7Stage IIIA Breast Cancer AJCC v7Stage IIIB Breast Cancer AJCC v7Stage IIIC Breast Cancer AJCC v7Stage IV Breast Cancer AJCC v6 and v7
This randomized phase II trial studies how well tamoxifen citrate works compared with z-endoxifen hydrochloride in treat…